High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFα treatment: correlation with disease activity

Clinical and Experimental Rheumatology

Volumn 27, Issue 2, 2009, Pages 292-298

  Papadakisl, J A ^a   Sidiropoulos, P I ^b   Karvounaris, S A ^b   Vrentzos, G E ^a   Spanakis, E K ^b   Ganotakis, E S ^a   Kritikos, H D ^b   Mikhailidis, D P ^c   Boumpas, D T ^a,b,d  

^a Department of Internal Medicine ^*  (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

Ankylosing spondylitis; Bath Ankylosing Spondylitis Disease Activity Index (BASDAI); Cardiovascular risk factors; Metabolic syndrome

Indexed keywords

ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ANKYLOSING SPONDYLITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; GREECE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 67249090150     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. HASKARD DO: Accelerated atherosclerosis in inflammatory rheumatic diseases. Scand J Rheumatol 2004; 33: 28 1-92.
2. HAN C. ROBINSON DW, HACKETT MV, PARAMORE LC FRAEMAN KH, BALA MV: Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 2167-72.
3. GAZI IF, BOUMPAS DT. MIKHAILIDIS DR GANOTAKIS ES: Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 2007; 25: 102-11.
4. DESSEIN PH, STANWIX AE, JOFFE BI: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002; 4: R5.
5. DESSEIN PH, STANWIX AE. MOOMAL Z: Rheumatoid arthritis and cardiovascular disease may share similar risk factors. Rheumatology 2001; 40: 703-4.
6. DIVECHA H, SATTAR N, RUMLEY A, CHERRY L, LOWE GD, STURROCK R: Cardiovascular risk parameters in men with ankylosing spondylitis in comparison to non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond) 2005: 109: 171-6.
7. GRUNDY SM, CLEEMAN JI, DANIELS SR et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart. Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
8. DASKALOPOULOU SS, MIKHAILIDIS DP, ELISAF M: Prevention and treatment of the metabolic syndrome. Angiology 2004; 55: 589-6 12.
9. LAAKSONEN DE. LAKKA HM. NISKANEN LK, KAPLAN GA, SALONEN JT, LAKKA TA: Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156: 1070-7.
10. LAKKA HM, LAAKSONEN DE, LAKKA TA et at.: The metabolic syndrome and total and cardiovascular disease mortality in middle- aged men. JAMA 2002; 288:2709-16.
11. GALASSI A, REYNOLDS K, HE J: Metabolic syndrome and risk of cardiovascular disease: a meta-analysis Am J Med 2006; 119: 812-9.
12. REAVEN GM: Banting lecture 1988. Role of insulin resistance in human disease. Diahetes 1988; 37: 1595-607.
13. HANLEY AJ, KARTER AJ, FESTA A et at.: Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 2642-7.
14. FERNANDEZ-REAL MJ, RICART W: Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Rev 2003; 24: 278-301.
15. YUDKIN iS, STEHOUWER CDA. EMEIS JJ. COPPACK SW: C-Reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscier Thromb Vasc Biol 1999; 19: 972-8.
16. VISSER M, BOUTER LM, MCQUILLAN GM, WENER MR. HARRIS TB: Elevated C-reactive protein levels in overweight and obese adults. J Am Med Assoc 1999; 282: 2131-5.
17. FROHLICH M, IMHOF A, BERG G et al.: Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-9.
18. FESTA A, D'AGOSTINO R JR. HOWARD G, MYKKANEN L, TRACY RP, HAFFNER SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
19. SAKKINEN PA, WAHL P. CUSHMAN M, LEWIS MR. TRACY RP: Clustering of pro- coagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000; 152: 897-907.
20. HAK AE, POLS HA. STEHOUWER CD et at.: Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J Clin Endocrinot Metabot 2001: 86: 4398-405.
21. SERIOLO B, PAOLINO 5, SULLI A, FASCIOLO D, CUTOLO M: Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann NY Acad Sci 2006; 1069: 414-9.
22. KELLER C, WEBB A, DAVIS J: Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis 2003; 62: 1128-32.
23. ANDREAKOS ET, FOXWELL BM, BRENNAN FM. MAINI RN, FELDMANN M: Cytokines and anti-cylokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev 2002; 13: 299-313.
24. LEHTINEN K: Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993; 52: 174-6.
25. PETERS MJ, VAN DER HORST-BRUINSMA IE, DIJKMANS BA, NURMOHAMED MT: Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004; 34: 585-92.
26. CHUNG CR AVALOS I, OESER A et at.: High frequency of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208-14.
27. KARvOuNARIS SA. SIDIROPOULOS Pt, PAPADAKIS JA et at.: Metabolic syndrome is common among middle - to older - age Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross- sectional, controlled, study. Ann Rheum Dis 2007; 66: 28-33.
28. MALESCI D. NIGLIO A, MENNILLO GA, BUONO R, VALENTINI G, LA MONTAGNA G: High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol 2007; 26: 710-4.
29. DOUGADOS M, VAN DER LINDEN S. JUHLIN R et al.: The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-27.
30. FURST DE. BREEDVELD FC. KALDEN JR et al.: Updated consensus statement on biological agents, specifically tumor necrosis factor-alpha (TNF-α) blocking agents and interleukin-l receptor antagonist (IL-lra). for the treatment of rheumatic diseases. Ann Rheum Dis 2005; 64 (Suppl.) 4: 2-14.
31. WHO EXPERT COMMIFFEE, PHYSICAl STATUS: the use and interpretation of anthropometry. WHO Tech Rep Ser 1995; 854: 424-38.
32. ANDERSON KM. WILSON PW. ODELL PM. KANNEL WB: An updated coronary risk profile. A statement for health professionals. Circulation 1991: 83: 356-62.
33. BRAUN J, PHAM T. SIEPER J et al.: International ASAS consensus statement for the use of anti-tumor necrosis agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003: 62: 8 17-24.
34. CALIN A. GARRETF S, WHITELOCK H et al.: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281-5.
35. ROSSNER S: Further studies on serum Iipoproteins in connective tissue diseases. Atherosclerosis 1978; 31: 93-9.
36. JOVEN J. RUBIES-PRAT J, RAS MR. DE LA FIGUERA M. LIENCE E, MASDEU S: High density lipoproteins cholesterol subfractions and apoprotein A-I in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum 1984; 27: 1199-2000.
37. MASI AT, ALDAG JC, MOHAN PC: Determinants of significantly lower serum total cholesterol levels in ankylosing spondylitis patients than age-, gender-, and medical service-matched controls patients: results of multivariate analysis. Arthritis Rheum 1999: 42 (Suppl.): S300.
38. ATHYROS VG, BOULOUKOS VI, PEHLIVANIDIS AN et al.: Mets-Greece Collaboration Group. The prevalence of the metabolic syndrome in Greece: the Mets-Greece Multicentre Study. Diabetes Ohes Metab 2005; 7: 397-405.
39. KIORTSIS ON, MAVRIDIS AK. VASAKOS S. NIKAS SN, DROSOS AA: Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 765-6.
40. SPANAKIS E. SIDIROPOULOS P. PAPADAKIS et al.: Modest But Sustained Increase of Serum High Density Lipoprotein Cholesterol Levels in Patients with Inflammatory Arthritides Treated with Infliximab. J Rheumatol 2006: 33: 2440-6.
41. POPA C. NETEA MG. RADSTAKE T et al.: Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheurn Dis 2005; 64: 303-5.
42. DUFFY O. RADER DJ: Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 2006:113: 1140-50.
43. KENNEDY MA. VENKATESWARAN A. TARR PT et al.: Characterization of the human ABCG1 gene: liver X receptor activates an internal J. promoter that produces a novel transcript encoding an alternative form of the protein. Biol Chem 2001; 276: 39438-47.
44. REPA JJ. BERGE KE. POMAJZL C, RICH ARDSON JA, HOBBS H. MANGELSDORF DJ: Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002; 277: 18793-800.
45. VAISMAN BL, LAMBERT G, AMAR M et al.: ABCAI over expression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 2001; 108: 303-9.
46. WANG Y. MOSER AH. SHIGENAGA 1K. GRUNFELD C. FEINGOLD KR: Down regulation of liver X receptor-alpha in mouse kidney and HK-2 proximal tubular cells by LPS and cytokines. J Lipid Res 2005: 46: 2377-87.
47. KODAMA S. TANAKA S. SAITO K et al.: Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med 2007 May 28: 167: 999-1008.
48. SPRECHER DL. WATKINS TR. BF.HAR S. BROWN WV. RUBINS HB. SCHAEFER EJ: Importance of high-density lipoprotein cholesterol and triglyceride levels in coronary heart disease. Am J Cardiol 2003: 91: 575-80.
49. ECKEL RH. GRUNDY SM. ZIMMET PZ: The metabolic syndrome. Lancet 2005: 365: 1415-28.
50. VAN HALM VP. VAN DENDEREN JC. PETERS MJ et al.: Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65: 1473-7.
51. HULTHE J. FAGERBERG B: Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study). Atherioscler Thronth Vasc Biol 2002: 22: 1162-7.
52. ROSS R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999: 340: 115-26.
53. PETERS M. SYMMONS D. MCCAREY D. NCRMOHAMED M: Cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis - A EULAR TASK FORCE. Arthritis Rheum 2008; 58: Suppl.